Drug Search Results
More Filters [+]

Ambrisentan

Alternative Names: ambrisentan, bsf 208075, letairis
Latest Update: 2024-02-13
Latest Update Note: Clinical Trial Update

Product Description

Ambrisentan is an oral medication classified as an endothelin receptor antagonist (ERA) which is approved for the treatment of pulmonary arterial hypertension (PAH) in World Health Organization (WHO) Group 1 patients. (Sourced from: https://phassociation.org/patients/treatments/ambrisentan/)

Mechanisms of Action: ET Antagonist

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: Hypertension | Iris Diseases | Hypertension, Pulmonary

Known Adverse Events: Headache | Anemia | Bronchitis | Sinusitis | Dyspepsia | Edema | Flushing

Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Ambrisentan

Countries in Clinic: Argentina, Canada, China, Denmark, Finland, France, Germany, Hungary, Italy, Japan, Netherlands, Russia, Spain, United States

Active Clinical Trial Count: 5

Highest Development Phases

Phase 2: Acute Kidney Injury|COVID-19|Diabetic Nephropathy|Hepatorenal Syndrome|Hypertension, Pulmonary|Liver Cirrhosis|Type 1 Diabetes

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

N-003-CRD005

P2

Not yet recruiting

Liver Cirrhosis|Hepatorenal Syndrome|Acute Kidney Injury

2025-03-01

24%

ASPIRE

P2

Not yet recruiting

Diabetic Nephropathy|Type 1 Diabetes

2025-03-01

2020-005104-20

P2

Active, not recruiting

COVID-19

2022-12-07

NCT01342952

P2

Completed

Hypertension, Pulmonary

2022-06-09

Recent News Events